Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF ...

Aashima Gupta leads health tech projects for the massive cloud computing company. Here, she shares why she’s excited about ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...

Credit to its robust bankability, supreme technological capability, and the worldly renowned 210mm n-type TOPCon modules ...

BCW is one of the first Web3 focused Google Cloud Partners in APAC that has achieved the Generative AI Partner Specialization. BCW is one o ...

Rockstar Games® is proud to announce the acquisition of Video Games Deluxe, the Sydney-based development studio. The studio will be renamed Rockstar Australia. Video Games Deluxe has worked with ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the trades showed up on ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Vertex Pharmaceuticals Inc.’s new non-opioid painkiller is being placed on a tier that means it might be costlier than other pain treatments on UnitedHealth Group Inc.’s approved drug lists.

Detailed price information for Vertex Resource Group Ltd (VTX-X) from The Globe and Mail including charting and trades.